Related Experiment Video
Updated: Nov 11, 2025
Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
Published on: July 16, 2018
Engineered cells as glioblastoma therapeutics
Aparna Ramanathan1, Ian A J Lorimer2,3,4
1Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Abstract:
In spite of significant recent advances in our understanding of the genetics and cell biology of glioblastoma, to date, this has not led to improved treatments for this cancer. In addition to small molecule, antibody, and engineered virus approaches, engineered cells are also being explored as glioblastoma therapeutics. This includes CAR-T cells, CAR-NK cells, as well as engineered neural stem cells and mesenchymal stem cells. Here we review the state of this field, starting with clinical trial studies. These have established the feasibility and safety of engineered cell therapies for glioblastoma and show some evidence for activity. Next, we review the preclinical literature and compare the strengths and weaknesses of various starting cell types for engineered cell therapies. Finally, we discuss future directions for this nascent but promising modality for glioblastoma therapy.
Insights
Engineered cell therapies show promise for glioblastoma treatment, with clinical trials demonstrating safety and feasibility. Further research into various cell types could lead to improved glioblastoma therapies.
Area of Science:
- Neuro-oncology
- Cellular therapy
- Cancer immunotherapy
Background:
- Despite advances in glioblastoma genetics and cell biology, effective treatments remain elusive.
- Engineered cell therapies, including CAR-T, CAR-NK, and stem cell approaches, are emerging as potential glioblastoma therapeutics.
Purpose of the Study:
- To review the current state of engineered cell therapies for glioblastoma.
- To evaluate clinical trial data and preclinical findings.
- To discuss future directions for this therapeutic modality.
Main Methods:
- Review of clinical trial studies on engineered cell therapies for glioblastoma.
- Analysis of preclinical literature comparing different engineered cell types.
- Discussion of future research and development pathways.
Main Results:
- Clinical trials confirm the feasibility and safety of engineered cell therapies for glioblastoma.
- Evidence of therapeutic activity has been observed in early-stage studies.
- Preclinical data highlight the strengths and weaknesses of various cell sources.
Conclusions:
- Engineered cell therapies represent a promising, albeit nascent, approach to glioblastoma treatment.
- Further investigation into optimizing cell types and therapeutic strategies is warranted.
- This field holds potential for significantly improving glioblastoma patient outcomes.
More Related Videos
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015